Virology News and Research

Latest Virology News and Research

New HPV vaccine eliminates chronic infection and reduces precancerous genital lesions in women

A new vaccine designed to stimulate an immune response against a cancer-causing human papillomavirus (HPV-16) can eliminate chronic infection by the virus and may cause regression of precancerous genital lesions in women who receive the vaccine.

11 Nov 2009

VeriChip announces the completion of Steel Vault acquisition

VeriChip Corporation, a provider of radio frequency identification (RFID) systems for healthcare and patient-related needs, and Steel Vault Corporation, a premier provider of identity security products and services, announced today that VeriChip has completed its acquisition of Steel Vault to provide unique health and security identification tools to protect consumers and businesses. In conjunction with the merger, VeriChip has changed its name to PositiveID ("PositiveID" or the "Company").

11 Nov 2009

HIV/AIDS leading cause of death among women ages 15-44, WHO study shows

In follow-up coverage to the WHO's report on women's health, several news outlets examine the impact HIV/AIDS is having on women around the world. "In its first study of women's health, the World Health Organization said yesterday that the AIDS virus is the leading cause of death and disease among women between the ages of 15 and 44," the Associated Press/Boston Globe reports (11/10).

11 Nov 2009

GSK to donate 50M H1N1 vaccine doses to WHO in coming months

Drugmaker GlaxoSmithKline announced plans on Tuesday to donate 50 million doses of its H1N1 (swine flu) vaccine to the WHO for use in developing countries within the next few months, Reuters reports. "We expect to start receiving [the first of the H1N1 doses] at the end of the month or early December and that the full 50 million will come by the end of spring," WHO spokesman Gregory Hartl said, adding, "We hope it is the first of many donations."

10 Nov 2009

Aduro BioTech raises funds through its Series A-1 financing

Aduro BioTech, a privately held biotechnology company focused on the development of therapeutic and prophylactic vaccines based on proprietary recombinant strains of the bacterium Listeria monocytogenes, today announced completion of its Series A-1 financing.

10 Nov 2009

BioVex completes $70M financing to complete OncoVEX Phase III study

BioVex Inc, a company developing new generation biologics for the treatment and prevention of cancer and infectious disease, announced today that it has concluded a $70 million private financing, raising $30 million in addition to the $40 million announced in March. The proceeds of the financing will primarily be used to complete the ongoing Phase III pivotal study of OncoVEX (GM-CSF) for the treatment of recurrent and metastatic melanoma and to fund pre-commercialization activities.

10 Nov 2009

HHS Secretary to visit Bradenton Healthcare Center to discuss the importance of H1N1 vaccinations

Health and Human Services Secretary Kathleen Sebelius will visit the East Manatee Family Healthcare Center in Bradenton, Fla. on Tuesday, November 10.

10 Nov 2009

NIH awards $6.8 million subcontract to Kineta to develop vaccine immune boosters

Kineta, Inc. announced today it has been awarded a $6.8 million subcontract from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop novel vaccine adjuvants (agents that help boost the immune system). The Kineta subcontract is part of a larger $13 million award to the University of Washington.

10 Nov 2009

AMP's four-day event on the latest advances in clinical molecular diagnostics

The Association for Molecular Pathology (AMP) invites the media to follow its upcoming 2009 Annual Meeting and Exhibits and learn about the latest advances in clinical molecular diagnostics.

10 Nov 2009

Exposure to common infections may increase stroke risk

Cumulative exposure to five common infection-causing pathogens may be associated with an increased risk of stroke, according to a report posted online today that will appear in the January 2010 print issue of Archives of Neurology, one of the JAMA/Archives journals.

10 Nov 2009

Study on how robust antibodies work to block the HIV virus raise hope for new vaccine

A very close and detailed study of how the most robust antibodies work to block the HIV virus as it seeks entry into healthy cells has revealed a new direction for researchers hoping to design an effective vaccine.

10 Nov 2009

H1N1 vaccine updates from Pennsylvania Department of Health

The federal Centers for Disease Control and Prevention, or CDC, has allocated a total of 1,351,400 doses of H1N1 vaccine to Pennsylvania to date, the state Department of Health announced today.

10 Nov 2009

New N95 respirator from Safe Life

Safe Life Corp., an innovative antimicrobial company dedicated to developing novel technologies that prevent the spread of infection and disease, announced today the availability of the Safe Life A400 Series N95 Respirator with Antimicrobial Protection.

10 Nov 2009

Human movement is a key factor for dengue spread in Brazil

Human movement is a key factor of dengue virus inflow in Rio de Janeiro, according to results from researchers based at the Oswaldo Cruz Foundation (Fiocruz) in Brazil. The results, based on data from a severe epidemic in 2007-2008, contribute to new understanding on the dynamics of dengue fever in the second largest city in Brazil. Details are published November 10 in the open-access journal PLoS Neglected Tropical Diseases.

10 Nov 2009

MicroDose Therapeutx acquires potential compounds for treatment of respiratory syncytial virus

MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA). The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.

10 Nov 2009

University of Michigan to develop novel therapy for neuropathic pain

Researchers from the University of Michigan Department of Neurology have received a $1.8 million dollar grant to develop a novel therapy for neuropathic pain, a difficult to treat condition in which patients experience pain because of damage to nerve without obvious tissue injury.

10 Nov 2009

H1N1 cases increase in China, Japan; Afghanistan attempts to contain virus

The WHO on Friday reported on a rising number of H1N1 (swine flu) cases in China and Japan, Reuters/Washington Post reports. "In China, after an earlier wave of mixed influenza activity (seasonal H3N2 and pandemic H1N1), pandemic H1N1 influenza activity now predominates and is increasing," the agency said. "Sharp increases in pandemic flu infections continue to be reported throughout Japan, particularly on the northern island," the news service writes (Nebehay, 11/6).

10 Nov 2009

TRICARE South Region beneficiaries urged to get H1N1 influenza vaccinations

Humana Military Healthcare Services, a wholly-owned subsidiary of Humana Inc. (NYSE: HUM), encourages TRICARE South Region beneficiaries to get their H1N1 influenza vaccinations in an effort to reduce the spread of the virus. Anticipating a greater need for the shots, the Department of Defense (DoD) is encouraging all military personnel to obtain the vaccines.

9 Nov 2009

NanoViricides to present data on its in vivo studies against influenza

NanoViricides, Inc., announced today that the Company’s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a panel discussion at the Influenza Congress USA 2009, in Washington DC on November 19th (www.terrapinn.com/usaflu). The discussion will center on the “Evolving Role of Anti-Virals” in influenza treatment.

9 Nov 2009

Cellular mechanisms that may impact immune functions in the elderly discovered

Investigators discover cellular mechanisms that may impact the decline of both innate and adaptive immune functions that increase the susceptibility to various infectious agents, cancer and diseases in the elderly say experts at the annual meeting of the American College of Allergy, Asthma and Immunology (ACAAI) in Miami Beach, Fla.

9 Nov 2009